Tinnitus treatment: Are drugs effective?

Audiological Medicine

Volumn 6, Issue 1, 2008, Pages 25-39

  Pyykkö, Ilmari ^a   Zou, Jing ^a   Kentala, Erna ^b   Stephens, Dafydd ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Central auditory pathway; Cochlear neurotransmission; Drug efficacy; Tinnitus alleviation

Indexed keywords

6,7 DINITRO 2,3 QUINOXALINEDIONE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANXIOLYTIC AGENT; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; BETAHISTINE; CALPAIN; CARBAMAZEPINE; DEXAMETHASONE; DEXTRO METHIONINE; DIZOCILPINE; GENTAMICIN; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; HYPNOTIC AGENT; KYNURENIC ACID; LIDOCAINE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ALTERNATIVE MEDICINE; CLINICAL TRIAL; COCHLEA INJURY; CYTOTOXICITY; HAIR CELL; HERBAL MEDICINE; HOMEOSTASIS; HUMAN; HYPERBARIC OXYGEN; MENIERE DISEASE; METABOLIC STRESS; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NONVIRAL GENE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; TINNITUS; UNSPECIFIED SIDE EFFECT;

EID: 41349112568     PISSN: 1651386X     EISSN: 16513835     Source Type: Journal    
DOI: 10.1080/16513860801948186     Document Type: Review

References (83)

1. Sand PG, Langguth B, Kleinjung T, Eichhammer P. Genetics of chronic tinnitus. Prog Brain Res. 2007;166:159-68.
2. Simpson JJ, Davies WE. Recent advances in the pharmacological treatment of tinnitus. Trends Pharmacol Sci. 1999;20:12-8.
3. Pyykkö I ZJ, Toppila E, Kentala E. Pharmacotherapy of the inner ear. In: Martini A, editor. Genes, Hearing and Deafness. London: Informa Healthcare; 2007. p. 219-38.
4. Oestreicher E, Wolfgang A, Felix D. Neurotransmission of the cochlear inner hair cell synapse: implications for inner ear therapy. Adv Otorhinolaryngol. 2002;59:131-9.
5. Pujol R, Puel JL, Gervais d'Aldin C, Eybalin M. Pathophysiology of the glutamatergic synapses in the cochlea. Acta Otolaryngol. 1993;113:330-4.
6. Puel JL, Ruel J, Guitton M, Wang J, Pujol R. The inner hair cell synaptic complex: physiology, pharmacology and new therapeutic strategies. Audiol Neurootol. 2002;7:49-54.
7. Puel JL. Chemical synaptic transmission in the cochlea. Prog Neurobiol. 1995;47:449-76.
8. Puel JL, Pujol R, Tribillac F, Ladrech S, Eybalin M. Excitatory amino acid antagonists protect cochlear auditory neurons from excitotoxicity. J Comparative Neurol. 1994;341:241-56.
9. Jager W, Goiny M, Herrera-Marschitz M, Brundin L, Fransson A, Canlon B. Noise-induced aspartate and glutamate efflux in the guinea pig cochlea and hearing loss. Experimental brain research Experimentelle Hirnforschung. 2000;134:426-34.
10. Bienkowski P, Scinska A, Kostowski W, Koros E, Kukwa A. Ototoxic mechanism of aminoglycoside antibiotics: role of glutaminergic NMDA receptors. Pol Merkur Lekarski. 2000;9:713-5.
11. Pulec JL. Cochlear nerve section for intractable tinnitus. Ear Nose Throat J. 1995;74:468, 470-6.
12. Wazen JJ, Foyt D, Sisti M. Selective cochlear neurectomy for debilitating tinnitus. Ann Otol Rhinol Laryngol. 1997;106:568-70.
13. Potashner SJ, Suneja SK, Benson CG. Regulation of Daspartate release and uptake in adult brainstem auditory nuclei after unilateral middle ear ossicle removal and cochlear ablation. Exp Neurol. 1997;148:222-35.
14. Makoff A, Pilling C, Harrington K, Emson P. Human metabotropic glutamate receptor type 7: molecular cloning and mRNA distribution in the CNS. Brain Res. 1996;40:165-70.
15. Langner G, Wallhäusser-Franke E, Mahlke C. Evidence for a central origin of tinnitus from activity labelling in the auditory system of the gerbil. Physiol Res. 1999;48:23.
16. Jastreboff PJ, Brennan JF, Coleman JK, Sasaki CT. Phantom auditory sensation in rats: an animal model for tinnitus. Behav Neurosci. 1988;102:811-22.
17. Masugi M, Yokoi M, Shigemoto R, Muguruma K, Watanabe Y, Sansig G, et al. Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion. J Neurosci. 1999;19:955-63.
18. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci. 2003;17:2409-17.
19. Sasaki CT, Kauer JS, Babitz L. Differential [14C]2-deoxyglucose uptake after deafferentation of the mammalian auditory pathway: a model for examining tinnitus. Brain Res. 1980;194:511-6.
20. Bilak M, Kim J, Potashner SJ, Bohne BA, Morest DK. New growth of axons in the cochlear nucleus of adult chinchillas after acoustic trauma. Exp Neurol. 1997;147:256-68.
21. Ruan RS, Leong SK, Yeoh KH. Ototoxicity of sodium nitroprusside is not due to nitric oxide. Exp Neurol. 1999;158:192-201.
22. Zdanski CJ, Prazma J, Petrusz P, Grossman G, Raynor E, Smith TL, et al. Nitric oxide synthase is an active enzyme in the spiral ganglion cells of the rat cochlea. Hear Res. 1994;79:39-47.
23. Johnson KL, Carrasco V, Prazma J, Zdanski CJ, Durland WF, Pillsbury HC. Role of nitric oxide in kainic acid-induced elevation of cochlear compound action potential thresholds. Acta Otolaryngol. 1998;118:660-5.
24. Amaee FR, Comis SD, Osborne MP, Drew S, Tarlow MJ. Possible involvement of nitric oxide in the sensorineural hearing loss of bacterial meningitis. Acta Otolaryngol. 1997;117:329-36.
25. Barkdull GC, Vu C, Keithley EM, Harris JP. Cochlear microperfusion: experimental evaluation of a potential new therapy for severe hearing loss caused by inflammation. Otol Neurotol. 2005;26:19-26.
26. Nakashima T, Naganawa S, Sone M, Tominaga M, Hayashi H, Yamamoto H, et al. Disorders of cochlear blood flow. Brain Res Rev. 2003;43:17-28.
27. Lamm K, Arnold W. Successful treatment of noise-induced cochlear ischaemia, hypoxia, and hearing loss. Ann N Y Acad Sci. 1999;884:233-48.
28. 2 and auditory function in the normal and noise-damaged hypoxic and ischaemic guinea pig inner ear. Hear Res. 2000;141:199-219.
29. Lamm K, Arnold W. Noise-induced cochlear hypoxia is intensity dependent, correlates with hearing loss and precedes reduction of cochlear blood flow. Audiol Neurootol. 1996;1:148-60.
30. Bennett MH, Kertesz T, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane database of systematic reviews (Online). 2007: CD004739.
31. Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol. 2004;29:226-31.
32. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: double-blind, placebo- controlled trial. Br Med J (Clinical research ed). 2001;322:73.
33. James AL, Burton MJ. Betahistine for Menière's disease or syndrome. Cochrane database of systematic reviews (Online). 2001:CD001873.
34. van Campen LE, Murphy WJ, Franks JR, Mathias PI, Toraason MA. Oxidative DNA damage is associated with intense noise exposure in the rat. Hear Res. 2002;164:29-38.
35. Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope. 1999;109:1740-4.
36. Wu WJ, Sha SH, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol. 2002;7:171-4.
37. Clerici WJ, Yang L. Direct effects of intraperilymphatic reactive oxygen species generation on cochlear function. Hear Res. 1996;101:14-22.
38. Neri S, Signorelli S, Pulvirenti D, Mauceri B, Cilio D, Bordonaro F, et al. Oxidative stress, nitric oxide, endothelial dysfunction and tinnitus. Free Radic Res. 2006;40:615-8.
39. Sha SH, Schacht J. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res. 2000;142:34-40.
40. Kopke RD, Weisskopf PA, Boone JL, Jackson RL, Wester DC, Hoffer ME, et al. Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla. Hear Res. 2000;149:138-46.
41. Zou J, Bretlau P, Pyykko I, Toppila E, Olovius NP, Stephanson N, et al. Comparison of the protective efficacy of neurotrophins and antioxidants for vibration-induced trauma. ORL J Otorhinolaryngol Relat Spec. 2003;65:155-61.
42. Puka-Sundvall M, Eriksson P, Nilsson M, Sandberg M, Lehmann A. Neurotoxicity of cysteine: interaction with glutamate. Brain Res. 1995;705:65-70.
43. Olzowy B, Canis M, Hempel JM, Mazurek B, Suckfull M. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. Otol Neurotol. 2007;Publish Ahead of Print.
44. Savastano M, Brescia G, Marioni G. Antioxidant therapy in idiopathic tinnitus: preliminary outcomes. Arch Med Res. 2007;38:456-9.
45. Khan M, Gross J, Haupt H, Jainz A, Niklowitz P, Scherer H, et al. A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol Head Neck Surg. 2007;136:72-7.
46. Puel J, Wang J, Rebillard G, Eybalin M, Lloyd R, Pujol R, et al. Physiology, pharmacology and plasticity at the inner hair cell synaptic complex. Hear Res. 2007;227:19-27.
47. Puel JL, Pujol R, Ladrech S, Eybalin M. Alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid electrophysiological and neurotoxic effects in the guinea-pig cochlea. Neuroscience. 1991;45:63-72.
48. Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol. 1997;117:825-30.
49. Salembier L, De Ridder D, van de Heyning PH. The use of flupirtine in treatment of tinnitus. Acta Otolaryngol Suppl. 2006;126 Suppl 556:93-5.
50. Attias J, Weisz G, Almog S, Shahar A, Wiener M, Joachims Z, et al. Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolaryngol. 1994;15:26-32.
51. Joachims Z, Netzer A, Ising H, Rebentisch E, Attias J, Weisz G, et al. Oral magnesium supplementation as prophylaxis for noise-induced hearing loss: results of a double-blind field study. Schriftenreihe des Vereins fur Wasser-, Boden- und Lufthygiene. 1993;88:503-16.
52. Araujo MF, Oliveira CA, Bahmad Jr FM. Intratympanic dexamethasone injections as a treatment for severe, disabling tinnitus: does it work? Arch Otolaryngol Head Neck Surg. 2005;131:113-7.
53. Sakata E, Itoh A, Itoh Y. Treatment of cochlear tinnitus with dexamethasone infusion into the tympanic cavity. Int Tinnitus J. 1996;2:129-35.
54. Sakata E, Ito Y, Itoh A. Clinical experiences of steroid targeting therapy to inner ear for control of tinnitus. Int Tinnitus J. 1997;3:117-21.
55. Sennaroglu L, Dini FM, Sennaroglu G, Gursel B, Ozkan S. Transtympanic dexamethasone application in Menière's disease: an alternative treatment for intractable vertigo. J Laryngol Otol. 1999;113:217-21.
56. Eklund S, Pyykko I, Aalto H, Ishizaki H, Vasama JP. Effect of intratympanic gentamicin on hearing and tinnitus in Menière's disease. Am J Otol. 1999;20:350-6.
57. Havia M, Kentala E, Pyykko I. Hearing loss and tinnitus in Menière's disease. Auris, nasus, larynx. 2002;29:115-9.
58. Yetiser S, Kertmen M. Intratympanic gentamicin in Menière's disease: the impact on tinnitus. Int J Audiol. 2002;41:363-70.
59. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg. 1993;119:842-5.
60. Vernon JA, Meikle MB. Masking devices and alprazolam treatment for tinnitus. Otolaryngol Clin North Am. 2003;36:307-20.
61. Huynh L, Fields S. Alprazolam for tinnitus. Ann Pharmacother. 1995;29:311-2.
62. Albertino S, Assuncao AR, Souza JA. Pulsatile tinnitus: treatment with clonazepam and propranolol. Revista brasileira de otorrinolaringologia (English edn). 2005;71:111-3.
63. Lopez-Gonzalez MA, Moliner-Peiro F, Alfaro-Garcia J, Esteban-Ortega F. Sulpiride plus hydroxyzine decrease tinnitus perception. Auris, nasus, larynx. 2007;34:23-7.
64. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). ENT J. 1996;75: 468-71, 474, 476 passim.
65. Megwalu UC, Finnell JE, Piccirillo JF. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg. 2006;134:210-3.
66. Bauer CA, Brozoski TJ. Gabapentin. Prog Brain Res. 2007;166:287-301.
67. den Hartigh J, Hilders CG, Schoemaker RC, Hulshof JH, Cohen AF, Vermeij P. Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration. Clin Pharmacol Ther. 1993;54:415-20.
68. Sanchez TG, Balbani AP, Bittar RS, Bento RF, Camara J. Lidocaine test in patients with tinnitus: rationale of accomplishment and relation to the treatment with carbamazepine. Auris, nasus, larynx. 1999;26:411-7.
69. Shea JJ, Harell M. Management of tinnitus aurium with lidocaine and carbamazepine. Laryngoscope. 1978;88:1477-84.
70. Piccirillo JF, Finnell J, Vlahiotis A, Chole RA, Spitznagel E Jr. Relief of idiopathic subjective tinnitus: is gabapentin effective? Arch Otolaryngol Head Neck Surg. 2007;133:390-7.
71. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: a pilot study. Otol Neurotol. 2007;28:11-5.
72. Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope. 2006;116:675-81.
73. Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: double-blind study. Revista brasileira de otorrinolaringologia (English edn). 2005;71:618-23.
74. Bahmad FM Jr, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J. 2006;12:140-4.
75. Trellakis S, Lautermann J, Lehnerdt G. Lidocaine: neurobiological targets and effects on the auditory system. Prog Brain Res. 2007;166:303-22.
76. Goodey RJ. Drugs in the treatment of tinnitus. Ciba Foundation symposium. 1981;85:263-78.
77. Pyykkö I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG. The effects of TTS-scopolamine, dimenhydrinate, lidocaine and tocainide on motion sickness, vertigo and nystagmus. Aviat Space Environ Med. 1985;56:777-82.
78. Savastano M. Lidocaine intradermal injection: a new approach in tinnitus therapy, preliminary report. Adv Therapy. 2004;21:13-20.
79. Emmett JR, Shea JJ. Treatment of tinnitus with tocainide hydrochloride. Otolaryngol Head Neck Surg. 1980;88:442-6.
80. Kawamoto K, Ishimoto S, Minoda R, Brough DE, Raphael Y. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci. 2003;23:4395-400.
81. Zou J, Saulnier P, Perrier T, Zhang Y, Manninen T, Toppila E, Pyykkö I. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J Biomed Materials Res: Part B-Applied Biomaterials. 2008 (in press).
82. Zenner HP, Ernst A. Cochlear-motor, transduction and signal-transfer tinnitus: models for three types of cochlear tinnitus. Eur Arch Otorhinolaryngol. 1993;249:447-54.
83. Rask-Andersen H, Boström M, Gerdin B, Kinnefors A, Nyberg G, Engstrand T, Miller JM, Lindholm D. Regeneration of human auditory nerve. In vitro/in video demonstration of neural progenitor cells in adults human and guinea pig spiral ganglion. Hear Res. 2005;203:180-91.